1,5-anhydro-2,3-dideoxy-3-{6-[(2-fluoropyridin-4-yl)methyl]-10-methyl-4-oxo-9,10-dihydropyrido[3,2-h]quinazolin-3(4H)-yl}-L-threo-pentitol | 1413974-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1,5-anhydro-2,3-dideoxy-3-{6-[(2-fluoropyridin-4-yl)methyl]-10-methyl-4-oxo-9,10-dihydropyrido[3,2-h]quinazolin-3(4H)-yl}-L-threo-pentitol
• 英文别名: 6-[(2-fluoropyridin-4-yl)methyl]-3-[(3R,4S)-3-hydroxyoxan-4-yl]-10-methyl-9H-pyrido[3,2-h]quinazolin-4-one
• CAS: 1413974-71-6
• 化学式: C₂₃H₂₃FN₄O₃
• 分子量: 422.459
• InChiKey: HYHBXBSXVKUWSO-OALUTQOASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  31
• 可旋转键数：
  3
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  78.3
• 氢给体数：
  1
• 氢受体数：
  7

文献信息

• N-METHYL TETRAHYDROQUINOLINE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Kuduk Scott D.

  公开号：US20150141444A1

  公开（公告）日：2015-05-21

  The present invention is directed to N-methyl tetrahydroquinoline compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及式(I)的N-甲基四氢喹啉化合物，它们是M1受体正向变构调节剂，可用于治疗涉及M1受体的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括这些化合物的制药组合物，以及利用这些化合物和组合物治疗由M1受体介导的疾病的用途。
• US9284312B2
  申请人：——

  公开号：US9284312B2

  公开（公告）日：2016-03-15